Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting
April 1, 2019New preclinical data highlights IPH5201 (anti-CD39) and IHP5301 (anti-CD73) neutralizing antibodies targeting the immunosuppressive adenosine pathway First data presented from Innate Pharma’s...2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
March 20, 2019Cash, cash equivalents and financial assets* amounted to €202.7m (million euros) as of December 31, 2018 (€176.6m in 2017) Revenue and other income amounted to €94.0m (€36.2m in 2017) Operating...Innate Pharma announces the appointment of Jennifer Butler as Executive Vice President, General Manager, US
March 12, 2019Commercial industry leader with immuno-oncology product launch experience joins Innate’s Executive Committee General Manager will lead the Lumoxiti ® transition to Innate Pharma from AstraZeneca...Innate Pharma announces appointment of Laure-Hélène Mercier to the Executive Board
February 12, 2019Appointments of Dr. Mondher Mahjoubi, Chief Executive Officer, and Dr. Yannis Morel, EVP Business Development and Portfolio Strategy, renewed to the Executive Board for three years Innate Pharma SA (...Innate Pharma receives FDA fast track designation for IPH4102 in relapsed or refractory Sézary syndrome
January 29, 2019Fast Track designation (FTD) is intended to expedite the development and regulatory review of IPH4102 for the treatment of adult patients with relapsed or refractory Sézary syndrome (SS) who have...Innate Pharma announces its financial calendar for 2019
January 10, 2019Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2019, which is set as follows: March 20, 2019: Publication of 2018 financial...
